OMB APPROVAL OMB NUMBER: 3235-0145 EXPIRES: OCTOBER 31, 1994 ESTIMATED AVERAGE BURDEN HOURS PER FORM...........14.90 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 15)* THE COOPER COMPANIES, INC. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $.10 per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 216648402 - -------------------------------------------------------------------------------- (CUSIP Number) Harold L. Schneider, Esq. Tenzer Greenblatt LLP 405 Lexington Avenue, New York, New York 10174 (212) 573-4348 - -------------------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notice and Communications) November 17, 1997 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. Check the following box if a fee is being paid with the statement [ ]. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7). NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP NO. 216648402 PAGE 2 OF 4 PAGES *SEE INSTRUCTIONS BEFORE FILLING OUT!
- ------------------------------------------------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Cooper Life Sciences, Inc. 94-2563513 - ------------------------------------------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] - ------------------------------------------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------------------------------------------ 4 SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------------------------------------------ 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------------------------------------------------------------------------------------------------ 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware - ------------------------------------------------------------------------------------------------------------------ 7 SOLE VOTING POWER NUMBER OF 492,133 shares of Common Stock SHARES --------------------------------------------------------------------------------------------------- BENEFICIALLY 8 SHARED VOTING POWER OWNED BY -0- EACH --------------------------------------------------------------------------------------------------- REPORTING 9 SOLE DISPOSITIVE POWER PERSON 492,133 shares of Common Stock WITH --------------------------------------------------------------------------------------------------- 10 SHARED DISPOSITIVE POWER -0- - ------------------------------------------------------------------------------------------------------------------ 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 492,133 shares of Common Stock - ------------------------------------------------------------------------------------------------------------------ 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------------------------------------------------------------------------------------------------ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.33% - ------------------------------------------------------------------------------------------------------------------ 14 TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------------------------------------------ This Amendment No. 15 amends and supplements Item 5 of the Schedule 13D filed with the Securities and Exchange Commission on June 22, 1992, as amended by Amendment No. 1 dated November 12, 1992, Amendment No. 2 dated July 6, 1993, Amendment No. 3 dated August 24, 1993, Amendment No. 4 dated July 14, 1994, Amendment No. 5 dated August 15, 1994, Amendment No. 6 dated September 6, 1994, Amendment No. 7 dated March 7, 1995, Amendment No. 8 dated August 27, 1996, Amendment No. 9 dated December 12, 1996, Amendment No. 10 dated February 10, 1997, Amendment No. 11 dated February 21, 1997, Amendment No. 12 dated March 6, 1997, Amendment No. 13 dated July 11, 1997 and Amendment No. 14 dated October 31, 1997 (as amended, the "Schedule 13D"), by Cooper Life Sciences, Inc., a Delaware corporation ("CLS"), relating to the Common Stock, par value $.10 per share (the "Common Stock") of The Cooper Companies, Inc., a Delaware corporation (the "Company"). Except as modified hereby, there has been no change in the information previously reported in the Schedule 13D. Item 5. Interest in Securities of Issuer. The number of shares of Common Stock which may be deemed to be beneficially owned by CLS has decreased by more than 1% of the number of shares of the class which are deemed to be outstanding. Said decrease is the result of open market sales of an aggregate of 501,300 shares of Common Stock, as more fully set forth on Schedule I hereto. Page 3 of 4 Pages SIGNATURE After reasonable inquiry, and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. COOPER LIFE SCIENCES, INC. By: /s/ Steven Rosenberg _________________________________ November 26, 1997 Name: Steven Rosenberg - ----------------- Title: Vice President Date Page 4 of 4 Pages SCHEDULE I TO AMENDMENT NO. 15 TO SCHEDULE 13D No. of Price Nature of Shares Per Transaction Date Sold Share* - ----------- ---- ------- -------- Sale 11/03/97 111,300 $37.1177 Sale 11/04/97 4,900 37.875 Sale 11/10/97 5,100 37.875 Sale 11/13/97 10,000 35.50 Sale 11/14/97 9,000 35.625 Sale 11/17/97 10,000 35.875 Sale 11/17/97 10,000 36.00 Sale 11/17/97 10,000 36.125 Sale 11/17/97 10,000 36.25 Sale 11/17/97 10,000 36.375 Sale 11/17/97 10,000 36.50 Sale 11/17/97 10,000 36.75 Sale 11/17/97 10,000 36.875 Sale 11/17/97 10,000 37.00 Sale 11/17/97 21,000 36.1667 Sale 11/18/97 10,000 37.125 Sale 11/18/97 10,000 37.25 Sale 11/18/97 10,000 37.375 Sale 11/18/97 10,000 37.50 Sale 11/18/97 10,000 37.625 Sale 11/18/97 10,000 37.75 Sale 11/18/97 10,000 37.875 Sale 11/18/97 10,000 38.00 Sale 11/18/97 10,000 38.125 Sale 11/18/97 10,000 38.25 Sale 11/18/97 10,000 38.375 Sale 11/18/97 10,000 38.50 Sale 11/18/97 10,000 38.625 Sale 11/18/97 10,000 38.75 Sale 11/19/97 10,000 38.875 Sale 11/19/97 10,000 39.00 Sale 11/19/97 10,000 39.125 Sale 11/19/97 10,000 39.25 Sale 11/19/97 10,000 39.38 Sale 11/19/97 10,000 39.50 Sale 11/19/97 10,000 39.625 Sale 11/20/97 10,000 39.75 Sale 11/20/97 10,000 39.875 Sale 11/20/97 10,000 40.00 Sale 11/20/97 10,000 40.125 TOTAL 501,300 - -------------------- * Before payment of commissions.